enGene plans to start its FDA filing for detalimogene voraplasmid in bladder cancer by year-end after longer follow-up in a single-arm trial. Mirum’s brelovitug met the primary endpoint in a second Phase 3 hepatitis D trial, adding evidence for its planned US filing. Also covered: BioNTech’s $205 million deal for Scholar Rock’s priority review voucher, PepGen’s PGN-EDODM1 splicing data in myotonic dystrophy type 1, Oyster Therapeutics’ financing for its tau program, and Summit’s November 14 FDA goal date for ivonescimab plus chemotherapy in EGFR-mutated lung cancer. This is the delayed November 11, 2026 edition, released November 12.Alex Mercer and Maya Patel host.SourcesenGene — LEGEND and filing planhttps://investors.engene.com/English/investor/press-releases/news-details/2026/enGene-to-Initiate-a-BLA-Submission-for-Detalimogene-by-Year-End-and-Reports-New-Data-from-LEGEND-Trial-Pivotal-Cohort-1-in-BCG-Unresponsive-NMIBC/default.aspxMirum — AZURE-4 and filing planhttps://ir.mirumpharma.com/news/news-details/2026/Mirum-Pharmaceuticals-Announces-Primary-Endpoint-Met-in-AZURE-4-Phase-3-Study-and-Highlights-Long-Term-Brelovitug-Data-Presented-at-AASLD/default.aspxBioNTech — priority review voucher agreementhttps://www.biontech.com/us/en/home/mediaroom/news/statements/2026/11/BioNTech-to-Acquire-US-FDA-Priority-Review-Voucher.htmlPepGen — FREEDOM2-DM1 and partial clinical holdhttps://investors.pepgen.com/node/9531/html4BIO Capital — Oyster Therapeutics financinghttps://www.4biocapital.com/single-post/oyster-series-aSummit Therapeutics — HARMONi and FDA goal datehttps://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Reports-Financial-Results-and-Operational-Progress-for-the-Third-Quarter-and-Nine-Months-Ended-September-30-2026/
The daily Closeout in under 15 minutes — trial readouts, FDA decisions, and the deal math behind them. Free.
Subscribe →